Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch

Press Release: Propella Therapeutics Granted U.S. Patent for New Treatment for Metastatic Prostate Cancer

Propella Therapeutics Inc., a leader in the development of innovative best-in-class prescription products, today announced the issuance of a U.S. patent for a new drug treatment for metastatic prostate cancer. The patent covers new molecules that are designed to provide significant advantages over the current standard of care.

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

Press Release: Leading Drug Innovator Reorganizes into Two Separate Companies

Vizuri Health Sciences LLC has completed a strategic reorganization to form two new corporations. The new entities are Propella Therapeutics Inc., focusing on prescription drugs, and Vizuri Health Sciences Consumer Healthcare Inc., developing non-prescription pain management products.

Press Release: New Osteoarthritis (OA) Treatment Guidelines Issued … Expert Medical Organization Conditionally Recommends the Use of Topical Capsaicin for Pain due to OA of the Knee

The American College of Rheumatology (ACR), an organization of physicians and health professionals that advances education, research, advocacy and practice support for the care of people with arthritis, has announced updated 2019 treatment guidelines for the management of OA of the hand, hip, and knee.